Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Maria Celeste Varela"'
Autor:
Maria Celeste Varela, Roberto R. Rosato, Matthew Ojeda Saavedra, Agustina Taglialegna, James J. Davis, Melanie Roch, Scott Wesley Long, Adriana E. Rosato, Rafael E Hernandez, Lucas R. Hoffman, Warren E. Rose
Publikováno v:
Communications Biology, Vol 3, Iss 1, Pp 1-10 (2020)
Communications Biology
Communications Biology
Chronic airways infection with methicillin-resistant Staphylococcus aureus (MRSA) is associated with worse respiratory disease cystic fibrosis (CF) patients. Ceftaroline is a cephalosporin that inhibits the penicillin-binding protein (PBP2a) uniquely
Publikováno v:
J Antimicrob Chemother
Background Tedizolid is a protein synthesis inhibitor in clinical use for the treatment of Gram-positive infections. Pulmonary MRSA infections are a growing problem in patients with cystic fibrosis (CF) and the efficacy of tedizolid-based therapy in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27f3f7a771baa0224aa1159f45337c94
https://europepmc.org/articles/PMC7850011/
https://europepmc.org/articles/PMC7850011/
Publikováno v:
mSphere, Vol 4, Iss 1 (2019)
mSphere, Vol 4, Iss 1, p e00557-18 (2019)
mSphere, Vol 4, Iss 1, p e00557-18 (2019)
Methicillin-resistant Staphylococcus aureus (MRSA) threatens human health in hospital and community settings. The lipopeptide antibiotic daptomycin (DAP) is a frequently used treatment option for MRSA infection. DAP exposure can cause bacterial resis
Methicillin-resistant Staphylococcus aureus (MRSA) acquisition in cystic fibrosis (CF) patients confers a worse clinical outcome with increased rate of declined lung function. Telavancin, an approved lipoglycopeptide used to treat infections due to S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae0a6a76bcf4ee28ca76883bf58bd542
https://doi.org/10.1101/319210
https://doi.org/10.1101/319210
Publikováno v:
Antimicrobial agents and chemotherapy. 62(9)
Methicillin-resistant Staphylococcus aureus (MRSA) acquisition in cystic fibrosis (CF) patients confers a clinical outcome worse than that in non-CF patients with an increased rate of declined lung function. Telavancin, an approved lipoglycopeptide u